BiotechTube

Endostatin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vestibular Schwannoma

Conditions

Vestibular Schwannoma, Neurofibromatosis Type 2

Trial Timeline

Jan 1, 2014 → Apr 1, 2016

NCT ID
NCT02104323

About Endostatin

Endostatin is a phase 2 stage product being developed by Tiantan Bio for Vestibular Schwannoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02104323. Target conditions include Vestibular Schwannoma, Neurofibromatosis Type 2.

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02104323Phase 2Completed

Competing Products

2 competing products in Vestibular Schwannoma

See all competitors
ProductCompanyStageHype Score
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
35
NilotinibNovartisPhase 2
27